World's Largest Resource for Cardiovascular Perfusion

Perfusion StaffingPerfusion Staffing
   +1 888-499-5672Login
Perfusion NewswireMain ZoneCalcium gluconate 10 percent Injections by Rx Formulations: Recall – Microbial Contamination

Calcium gluconate 10 percent Injections by Rx Formulations: Recall – Microbial Contamination

Main Zone, Mobile Zone, Warnings and Recalls

[Posted 02/07/2014]

AUDIENCE: Health Professional, Risk Manager, Patient

ISSUE: FDA notified healthcare professionals to follow up with patients who received calcium gluconate 10% injections made by Rx Formulations, Mesa, Ariz., between Nov. 7 and Dec. 11, 2013. FDA testing confirmed the presence of microbial contamination in lot #778961 of Rx Formulations’ calcium gluconate injection product. The testing identified gram-positive rod bacteria in the product. A contaminated injectable drug can put patients at risk of adverse health consequences and possibly a serious infection.

BACKGROUND: Rx Formulations recalled products marketed as sterile on December 13, 2013.

RECOMMENDATION: Health care providers and hospital staff should immediately check their medical supplies, and quarantine the affected products.

Patients who were administered any drug marketed as sterile produced by Rx Formulations between Nov. 7 and Dec. 11, 2013, and who have concerns, should contact their health care provider.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program:

  • Complete and submit the report Online: www.fda.gov/MedWatch/report.htm
  • Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

[02/06/2014 – FDA Drug Safety Statement – FDA] 

Leave a Reply

You may also like
Blood Management, Education Zone, Pediatric Zone, Perfusion Zone, Tiny Perfusion Letter

Association Between Cyanosis, Transfusion, and Thrombotic Complications in Neonates and Children Undergoing Cardiac Surgery

Children with congenital heart defects are at increased risk for perioperative bleeding and postoperative thrombosis. In this study, the authors sought to develop a predictive model for postoperative thrombotic complications that integrates intraoperative bleeding and the requirement for allogenic blood products in addition to known patient and surgical characteristics.
Blood Management, Perfusion Zone, Tiny Perfusion Letter

Hemolysis Testing In Vitro: A Review of Challenges and Potential Improvements

In this article, the main challenges of hemolysis testing are described, namely the difficult blood sourcing, the high experimental workload, and the low reproducibility of test results. Several approaches to address the challenges identified are proposed and the respective literature is reviewed. These include the replacement of blood as the “shear-sensitive fluid” by alternative test fluids, the replacement of sparse, manual sampling and blood damage assessment by a continuous and automated monitoring, as well as an analysis of categories and causes of variability in hemolysis test results that may serve as a structural template for future studies.

Join TodayJoin Today